GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OXC-101 overview

OXC-101 (TH-1579/Karonudib) is under investigation for the treatment of metastatic melanoma, relapsed and refractory acute lymphocytic leukemia, acute myeloid leukemia, diffuse large B-cell lymphoma, burkitt lymphoma, multiple myeloma, myelodysplastic syndrome and solid malignant tumors. The drug candidate is administered through oral route as a solution. It acts by targeting 7,8-dihydro-8-oxoguanine triphosphatase (MTH1).

Oxcia overview

Oxcia is a pharmaceutical manufacturing company. Oxcia is headquartered in Stockholm, Sweden.

For a complete picture of OXC-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.